Jazz Pharmaceuticals (JAZZ)
Develops rare-disease medicines across sleep, epilepsy and oncology.
Something off on this page? Send us feedback.
Develops rare-disease medicines across neuroscience and oncology. Revenue comes from oxybate-based sleep treatments, Epidiolex/Epidyolex for rare epilepsies, and a growing set of cancer therapies, with commercialization shaped by regulatory approvals, payer coverage, supply continuity, and generic competition in high-sodium oxybate.
Develops and commercializes medicines for rare diseases across neuroscience and oncology, with sleep and epilepsy franchises alongside a growing group of cancer therapies. Xywav and Xyrem anchor oxybate-based sleep medicine, while Epidiolex/Epidyolex treats rare epilepsies.
Brings acquired, licensed and internally developed products into shared commercial capabilities. Oncology brands include Rylaze/Enrylaze, Zepzelca, Defitelio/defibrotide, Vyxeos, Ziihera and Modeyso, and the portfolio reaches patients internationally from an Irish headquarters.
Depends on continued commercialization of Xywav and Epidiolex/Epidyolex, successful oncology launches and development, regulatory approvals and post-approval commitments, payer coverage, and reliable manufacturing and supply. High-sodium oxybate also faces generic competition.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | UBS | Reiterate | Rating: —Target: $315 | Target: $337 |
| Sep 10, 2026 | Barclays | Reiterate | Rating: —Target: $270 | Target: $271 |
| Aug 28, 2026 | RBC Capital | Target | Target: $277 | Target: $299 |
| Aug 26, 2026 | RBC Capital | Reiterate | Rating: —Target: $194 | Target: $277 |
| Aug 26, 2026 | Truist Financial | Target | Target: $300 | Target: $281 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.20B · Total debt $4.41B · Total assets $11.08B · Shareholders' equity $4.80B
- Revenue
- $1.21B
- Operating income
- $248.2M
- Net income
- $192.8M
No dividends on record.
| Institutions | 99.87% | 64.83M shares | |
|---|---|---|---|
| 662 holders · as of Jun 30, 2026 | |||
| Insiders | 1.51% | 978.3K shares | |
| 20 holders · as of Sep 14, 2026 | |||
| Adds to | 101.38% | ||
64.91M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 101.38%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.19% | 5.97M | as of Jun 30, 2026 |
FMR LLCInstitution | 7.10% | 4.61M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.68% | 3.04M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.20% | 2.73M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 4.16% | 2.70M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Neena M. Patil | officer: EVP & Chief Legal Officer | −1,200 | $240.94 |
| Sep 8, 2026 | Renee D. Gala | officer: President & CEO | −2,000 | $243.03 |
| Sep 1, 2026 | Bruce C. Cozadd | director | −6,000 | $250.13 |
| Aug 27, 2026 | Robert Iannone | officer: EVP, Global Head of R&D & CMO | −76,921 | $249.70 |
| Aug 3, 2026 | Bruce C. Cozadd | director | −6,000 | $252.98 |
- Alkermes
Oxybate rival in narcolepsy and idiopathic hypersomnia
- Amneal Pharmaceuticals
Generic sodium oxybate rival to the legacy Xyrem franchise
- AstraZeneca (ADR)
Oncology overlap in small-cell lung cancer and HER2-positive tumors
- AbbVie
AML regimen rival through Venclexta-based combinations
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals | $241.46 | −0.00% | $15.17B | 16.5 | 9.6 | 3.3 | +15.6% |
| Alkermes | $43.72 | −1.04% | $7.41B | 115.4 | — | 4.4 | +27.0% |
| Amneal Pharmaceuticals | $19.51 | −3.22% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| AstraZeneca (ADR) | $167.91 | −0.11% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| AbbVie | $263.53 | −0.36% | $467.37B | 74.5 | 17.3 | 7.3 | +10.2% |
| Median | 57.9 | 17.3 | 4.3 | +10.0% |